5467

PPARD

peroxisome proliferator-activated receptor delta;PPARD;peroxisome proliferator-activated receptor delta

PPAR-beta|PPAR-delta|nuclear hormone receptor 1|nuclear receptor subfamily 1 group C member 2|peroxisome proliferator-activated nuclear receptor beta/delta variant 2|peroxisome proliferator-activated receptor beta

6p21.2

protein-coding

BACKGROUND: The role of peroxisome proliferator-activated receptor delta (PPAR delta) in the development and progression of colorectal cancer (CRC) remains controversial. AIMS: We investigated the impact of PPAR delta expression in tissues on liver metastasis of CRC. METHODS: We analyzed samples of primary CRC and matched normal adjacent tissues from 52 patients for the expression of PPAR delta, cyclooxygenase (COX)-2, vascular endothelial growth factor (VEGF)-A, and CXC chemokine receptor 4 (CXCR4). Correlations of the molecules expressions with clinical characteristics and prognosis of patients were studied. RESULTS: The number of patients positive for PPAR delta, COX-2, CXCR4, and VEGF-A was 25, 33, 18, and 19, respectively. Among the PPAR delta (+)/COX-2 (+), PPAR delta (-)/COX-2 (+), PPAR delta (+)/COX-2 (-), and PPAR delta (-)/COX-2 (-) patient groups, PPAR delta (+)/COX-2 (+) patients had the highest incidence of liver metastasis (p<0.01). PPAR delta (+)/COX-2 (+) expression was a significant independent prognostic factor (HR=7.108, 95% CI 1.231-41.029, p=0.0283) by Cox proportional analysis. PPAR delta (+)/COX-2 (+) patients had the highest positivity for CXCR4 or VEGF-A in tissues (p<0.01). Among the patients in the CXCR4 (+)/VEGF-A (+), CXCR4 (+)/VEGF-A (-), CXCR4 (-)/VEGF-A (+), and CXCR4 (-)/VEGF-A (-) groups, CXCR4 (+)/VEGF-A (+) patients had the highest incidence of liver metastasis (p<0.01). CONCLUSIONS: The expression of both PPAR delta and COX-2 in tissues may lead to liver metastasis and consequent poor prognosis in CRC patients.

AIM: To explore the possible relationship between expression of PPAR(pevoxisome prodiferator adivated receptor) beta and clinical pathological features of epithelial ovarian carcinoma (EOC). METHODS: PPARbeta expressions in normal ovaries (n=10), ovarian bordline tumors (n=10), and ovarian serous cystadenocarcinomas (n=46) were investigated by immunohistochemistry and RT-PCR. RESULTS: PPARbeta protein was expressed in normal ovaries and ovarian cancer. PPARbeta protein was found in cytoplasm of tumor cell. PPARbeta expression was 20% revealed in normal ovaries, 50% in bordline tumors 89.1% in serous cystadenocarcinomas(P<0.05), significantly higher than that in bordline tumors (P<0.05). PPARbeta expression was positively correlated with tumor stage, histological grade and lymphonode metastasis (P<0.05). CONCLUSION: High expression of PPARbeta may be related with the differentiation and metastasis of epithelial ovarian carcinoma.